Biotech Values

[genisi]

One more flashback from Downey: In a Teva/Barr luncheon in July 2008, he indicated that Barr/Pliva previously analyzed the generic Copaxone opportunity, but rejected it due to the product complexity, undefined regulatory pathway and patent portfolio.

http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=6056619&SessionID=7RJtWShufhMXAg7

Scroll to page 16